Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Net Margin (2016 - 2025)

Historic Net Margin for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to 209.83%.

  • ImmunityBio's Net Margin rose 11945600.0% to 209.83% in Q3 2025 from the same period last year, while for Sep 2025 it was 422.41%, marking a year-over-year increase of 75955900.0%. This contributed to the annual value of 2805.32% for FY2024, which is 910615600.0% up from last year.
  • ImmunityBio's Net Margin amounted to 209.83% in Q3 2025, which was up 11945600.0% from 350.44% recorded in Q2 2025.
  • ImmunityBio's Net Margin's 5-year high stood at 209.83% during Q3 2025, with a 5-year trough of 735700.0% in Q1 2022.
  • Moreover, its 5-year median value for Net Margin was 57900.0% (2021), whereas its average is 131407.41%.
  • In the last 5 years, ImmunityBio's Net Margin crashed by 2000000000bps in 2022 and then skyrocketed by 2000000000bps in 2023.
  • Over the past 5 years, ImmunityBio's Net Margin (Quarter) stood at 23475.13% in 2021, then tumbled by -532bps to 148391.78% in 2022, then decreased by -13bps to 167923.74% in 2023, then surged by 100bps to 783.62% in 2024, then skyrocketed by 73bps to 209.83% in 2025.
  • Its last three reported values are 209.83% in Q3 2025, 350.44% for Q2 2025, and 785.05% during Q1 2025.